A
Andrea Bezjak
Researcher at Princess Margaret Cancer Centre
Publications - 293
Citations - 20806
Andrea Bezjak is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Lung cancer & Radiation therapy. The author has an hindex of 62, co-authored 277 publications receiving 19027 citations. Previous affiliations of Andrea Bezjak include Ontario Institute for Cancer Research & University Health Network.
Papers
More filters
Journal ArticleDOI
Erlotinib in previously treated non-small-cell lung cancer.
Frances A. Shepherd,José Rodrigues Pereira,Tudor Ciuleanu,Eng Huat Tan,Vera Hirsh,Sumitra Thongprasert,Daniel Campos,Savitree Maoleekoonpiroj,Michael Smylie,Renato G. Martins,Maximiliano Van Kooten,Mircea Dediu,B. Findlay,Dongsheng Tu,Dianne Johnston,Andrea Bezjak,Gary M. Clark,Pedro Santabárbara,Lesley Seymour +18 more
TL;DR: Elotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy, and five percent of patients discontinued erlot inib because of toxic effects.
Journal ArticleDOI
Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer
Robert Timmerman,Rebecca Paulus,James M. Galvin,Jeff M. Michalski,William L. Straube,Jeffrey D. Bradley,Achilles J. Fakiris,Andrea Bezjak,Gregory M.M. Videtic,David W. Johnstone,Jack F. Fowler,Elizabeth Gore,Hak Choy +12 more
TL;DR: Patients with inoperable non-small cell lung cancer who received stereotactic body radiation therapy had a survival rate of 55.8% at 3 years, high rates of local tumor control, and moderate treatment-related morbidity.
Journal ArticleDOI
Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases
TL;DR: Meta-analysis of reported randomized trials shows no significant difference in complete and overall pain relief between single and multifraction palliative RT for bone metastases.
Journal ArticleDOI
Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial
Christina A. Meyers,Jennifer A. Smith,Andrea Bezjak,Minesh P. Mehta,James Liebmann,Timothy M Illidge,Ian Kunkler,Jean-Michel Caudrelier,Peter D. Eisenberg,J.H. Meerwaldt,Ross Siemers,Christian Carrie,Laiirie E. Gaspar,Walter J. Curran,S Phan,Richard A. Miller,Markus F. Renschler +16 more
TL;DR: Although the addition of MGd to WBRT did not produce a significant overall improvement between treatment arms, MGd may improve memory and executive function and prolong time to neurocognitive and neurologic progression in patients with brain metastases from lung cancer.
Journal ArticleDOI
Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases
Minesh P. Mehta,P. Rodrigus,C. Terhaard,Aroor R. Rao,John H. Suh,Wilson Roa,Luis Souhami,Andrea Bezjak,Mark H. Leibenhaut,Ritsuko Komaki,Christopher J. Schultz,Robert Timmerman,Walter J. Curran,Jennifer G. Smith,S Phan,Richard A. Miller,Markus F. Renschler +16 more
TL;DR: The overall results did not demonstrate significant differences by treatment arm for survival and ERC time to neurologic progression and investigator neurologic assessments demonstrated an MGd treatment benefit in all patients.